Researchers with Columbia University Vagelos College of Physicians and Surgeons will lead a new clinical trial involving vaccines that can help treat opioid use disorders. Even though drugs are available to help those who have opioid addiction to overcome the problem, relapse is very common – something durable vaccine can help prevent.
With this clinical trial launch, this research will officially mark the first time experimental vaccine has been tested in the US to have the potential to treat opioid abuse. The new vaccine came in the midst of sustainable problems with opioid abuse throughout the country, the public health crisis that experienced a large setback with a pandemic.
Vaccines – which are still experimental today – developed by the University of Minnesota Medical School’s Marco Pravetoni; This works by preventing oxycodone into the brain causing ‘high’ related to opioids. Blocks are made possible by the development of antibodies triggered by vaccines.
Assuming someone is vaccinated with an experimental vaccine, they will not be high after taking oxycodone because anti-oxycodone antibodies that are targeting before they can reach the brain. By blocking drug access to the brain, vaccines can also help prevent breathing deaths that often occur when someone overdose on opioid substances.
Vaccines so far are pracinate test subjects involving animal models. Based on the study, scientists found that vaccines reduce the number of opioid animals managed themselves and also protect them to various toxic overdose signs. Even better, vaccines will not interfere with Naloxon and other medications.
Going forward, clinical trials will involve three groups of people who use opioids but who do not receive other treatments for them. One group of participants will be given a low dose vaccine, another group will be given high doses, and the third group will be given a placebo. To begin, the researchers will evaluate safety, tolerability of vaccines, and how effectively stimulate the production of antibodies to the recipient.